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 Introduction 
 Topical antifungal therapy is well accepted for the 
management of cutaneous dermatophyte infections  [1] . 
Terbinafine, a synthetic allylamine, exerts a potent broad-
spectrum fungicidal activity by inhibiting squalene ep-
oxidase. The interference with sterol synthesis is selective 
for fungal enzymes and has little impact on the choles-
terol biosynthesis of mammals  [2] . Various topical forms 
of terbinafine (Lamisil  ; cream, gel and spray solution) 
have been approved and are available for the treatment of 
dermatomycoses in many countries. A 1-week treatment 
with once daily application for interdigital-type tinea pe-
dis has been approved for these topical forms in European 
countries. Most recently, a new single-application formu-
lation was specifically developed and approved for tinea 
pedis – terbinafine 1% in a film-forming solution (FFS) 
(Lamisil Once, Lamisil Pedisan Once). Here we describe 
the scientific rationale that allows a single-application 
therapy in cutaneous mycosis. This takes into account the 
specific features of terbinafine and the new FFS.
 Antifungal Activity of Terbinafine 
 In approximately 98% of the cases, dermatophytes are 
the pathogens causing fungal infections of the foot  [3–6] . 
In vitro susceptibility tests have shown that terbinafine 
exerts primarily fungicidal activity against dermato-
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 Abstract 
 Terbinafine, a synthetic allylamine, exerts fungicidal activity 
against dermatophytes, the causative pathogens of tinea 
pedis. As proven in numerous clinical trials, tinea pedis can 
be effectively and safely treated by topical terbinafine. In 
fact, a 1-week application of terbinafine 1% cream eradicat-
ed fungal pathogens at least as effectively as 4-week treat-
ment courses with topical azole derivative antifungals and 
showed lower relapse rates. A new innovative single-appli-
cation formulation of terbinafine 1% in a film-forming solu-
tion produces a high concentration gradient on the skin sur-
face and enables a prolonged (up to 13 days) exposure of the 
skin to terbinafine. High drug penetration into the skin re-
sults in an otherwise not obtained drug reservoir in the 
horny layer, the location of dermatophytes in tinea pedis. 
Although azole antimycotics can also effectively penetrate 
into the horny layer of the skin, short-term therapy might not 
be feasible due to its primarily fungistatic activity against 
dermatophytes. Thus, we conclude that the high efficacy of 
short-term treatment with terbinafine in patients with tinea 
pedis is possible due to its fungicidal activity coupled with a 
distinct reservoir formation in the upper layers of the epider-
mis.  Copyright © 2008 S. Karger AG, Basel 
 Received: May 25, 2007 
 Accepted: September 28, 2007 
 Published online: May 29, 2008 
 Prof. Dr. phil. nat. Monika Schäfer-Korting 
 Department of Pharmacy,  Freie Universität Berlin
Königin-Luise-Strasse 2–4 
 DE–14195 Berlin (Germany) 
 Tel. +49 30 8385 3283, Fax +49 30 8385 4399, E-Mail msk@zedat.fu-berlin.de 
 © 2008 S. Karger AG, Basel
1660–5527/08/0214–0203$24.50/0 
 Accessible online at:
www.karger.com/spp 
 Schäfer-Korting /Schoellmann /Korting 
 
Skin Pharmacol Physiol 2008;21:203–210204
phytes,  Aspergillus spp.,  Scopulariopsis brevicaulis,  Blasto-
myces dermatitidis,  Histoplasma capsulatum and  Candida 
parapsilosis, while a fungistatic activity is seen against  C. 
albicans  [7] . In vitro terbinafine is most active ( fig. 1 ) 
against dermatophytes such as  Trichophyton, Microspo-
rum  and  Epidermophyton spp.  [8] , with minimum inhibi-
tory concentrations of 0.001–0.05   g/ml  [9–11] . For terbi-
nafine, the minimum fungicidal concentrations for der-
matophytes are comparable to its minimum inhibitory 
concentrations  [10, 12] . Thus, terbinafine eliminates fungi 
at concentrations that are several magnitudes below those 
found with azole derivatives, which exert fungistatic ac-
tivity, the minimum inhibitory concentration range main-
ly spreading from 0.1 to  1 10   g/ml. In fact, the in vitro 
 activity of terbinafine against dermatophytes as a rule ex-
ceeds the activity of other antifungal agents  [9, 13] .
 Efficacy of Terbinafine in Comparison with Placebo 
and Azole Antifungal Agents 
 A number of placebo-controlled and active compara-
tor (including topically applied antifungal azoles) trials 
have examined the efficacy of topical terbinafine in pa-
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 Fig. 1. Distribution of the minimum in-
hibitory concentrations (MIC) of 6 antimi-
crobial agents against 48  Trichophyton ru-
brum and  T. mentagrophytes strains iso-
lated from infected nail plates in 7 
dermatological centers from various parts 
of Germany.  + =  T. rubrum ;  _ =  T. men-
tagrophytes  [9] .  a Griseofulvin.  b Ketocon-
azole.  c Itraconazole.  d Fluconazole.  e Ter-
binafine.  f Ciclopiroxolamine. 
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tients with tinea pedis. A review of 8 placebo-controlled 
trials reported topical terbinafine therapy to produce my-
cological cure rates significantly superior to those found 
with placebo ranging from 81 to 100% within 6–8 weeks 
 [13] . In these clinical studies, 703 patients with tinea pe-
dis were treated with terbinafine 1% cream, solution, gel 
or placebo once or twice daily for 1–4 weeks, with 1-week 
application being the most common mode of use. Differ-
ent treatment periods and frequencies resulted in similar 
mycological and clinical cure rates  [14–21] .
 Several well-controlled trials comparing the efficacy 
of topical terbinafine to topical antifungal azoles in 1,523 
patients with tinea pedis have been published [for review 
see  22, 23 ]. Terbinafine 1% cream or solution was applied 
once or twice daily for 1 or 2 weeks, while azole-contain-
ing topicals were used for 4 weeks in most studies. In 1 
study, bifonazole cream was applied for 2 weeks  [24] , in 
another oxiconazole cream was applied for 2 weeks  [25] . 
Mycological response to the therapy was evaluated by 
culture up to 11 weeks after the end of treatment. These 
studies show terbinafine has similar efficacy compared 
to clotrimazole, miconazole, bifonazole or oxiconazole 
but with shorter duration of treatment. As the treatment 
duration with terbinafine was shorter in most cases, this 
suggests its superior effectiveness  [26–31] . Furthermore, 
some studies have described a higher clinical cure rate 
following terbinafine as compared to the azole treatment 
despite shorter duration of treatment  [25–28, 32] . Most 
interestingly, the mycological and clinical cure rates con-
tinued to increase after the end of the 1-week terbinafine 
treatment  [25–28] . Relapse/reinfection rates (made evi-
dent by reversion to positive culture) were less frequent 
in the terbinafine groups than in patients receiving 
clotrimazole. Approximately 30% of the ‘cured’ patients 
had a relapse/reinfection within 8 weeks after treatment 
with a 4-week course of clotrimazole cream. By compar-
ison,  ! 10% of the cured patients treated with terbinafine 
cream for 1 week had relapse/reinfection by 11 weeks af-
ter treatment  [26] .
 Most recently, a single application using a new terbin-
afine 1% FFS was shown to be effective in the treatment 
of tinea pedis as demonstrated by 2 vehicle-controlled 
double-blind studies. In a dose-finding study of 536 pa-
tients with tinea pedis, terbinafine 1% FFS resulted in a 
mycological cure rate of 84% compared to only 27% with 
the vehicle  [33] . In a second study, 190 patients with in-
terdigital-type tinea pedis were treated with terbinafine 
1% FFS and 83 with the vehicle. After 6 weeks, mycolog-
ical cure was achieved in 72% of the patients receiving 
terbinafine 1% FFS compared to 21% of the patients who 
received the vehicle  [34] . The relapse/reinfection rate of 
cured patients (12.5%) 3 months after the end of the sin-
gle-dose therapy was similar to that previously seen when 
using terbinafine 1% cream for 7 days (9.3%)  [26, 34] . 
Thus, in both studies terbinafine 1% FFS was significant-
ly superior over the vehicle and the cure rates were close 
to those with 7-day treatment of terbinafine 1% cream 
applied once or twice daily  [35] .
 Three systematic reviews report a low incidence of side 
effects for both terbinafine and the azoles  [13, 22, 23] . 
Similarly, single-application terbinafine 1% FFS has also 
shown a low incidence of side effects  [34, 36] . Thus, ter-
binafine is as effective and safe as azoles but is superior 
with regards to effectiveness based on its remarkably 
short treatment duration (i.e. 1 week for cream, gel and 
solution; single application for FFS).
 Effect of Terbinafine over Time 
 Clinical studies have shown that terbinafine provides 
continued increase in cure rates for days to weeks after 
discontinuation of treatment in patients with tinea pedis. 
This holds true both for the oral and topical route of ap-
plication. An early placebo-controlled study evaluating 
the efficacy of oral terbinafine (125 mg b.i.d for 6 weeks) 
for moccasin-type tinea pedis showed a complete cure in 
59% of the patients at the end of therapy and 65% after an 
additional 2 weeks  [37] . As a result, significantly shorter 
treatment periods were subsequently tested. In fact, oral 
administration of terbinafine 250 mg/day for 2 weeks in-
duced a complete cure within 4–6 weeks after the end of 
the therapy in 80–90% of the patients with dermatophyte 
infections of the feet or hands [for review see  8 ].
 An increase in cure rates after treatment cessation has 
also been observed following topical application of terbi-
nafine. The application of terbinafine 1% cream twice 
daily for 1 week resulted in the eradication of dermato-
phytes in 93.5% within 4 weeks after the end of treatment, 
and this rate increased to 97.2% at 6 weeks after treatment 
 [27] . In a randomized controlled trial of 100 patients with 
tinea pedis treated with terbinafine 1% cream once daily 
for 7 days, mycological cure was reported in 50% of the 
patients immediately following discontinuation of treat-
ment, which increased to 91.4% at 7 weeks after treatment 
 [16] . The authors concluded that the increasing efficacy 
of terbinafine after the end of the treatment period can 
be accounted for not only by the fungicidal effect but also 
in particular by its favorable pharmacokinetic character-
istics of substantial and rapid penetration into the stra-
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tum corneum and remanence in the tissue for a long time 
after discontinuation of treatment. This is particularly 
evident with the new terbinafine formulation, where the 
cure rates continue to increase for up to 6 weeks after a 
single application  [36] .
 Skin and Plasma Pharmacokinetics of Terbinafine 
 Based on several studies conducted in humans  [36, 
38–41] and animals  [42, 43] , it has been noted that terbi-
nafine accumulates in the skin after topical or oral appli-
cation and persists at high concentrations up to several 
weeks after discontinuation of drug application. Being 
highly lipophilic, terbinafine attaches to keratinocytes 
and thereby remains in the stratum corneum for a long 
time  [44] . Terbinafine also accumulates in the nails, hair, 
dermis/epidermis and in subcutaneous fat tissues  [39, 40] 
after oral treatment. Long-term retention in the skin is 
also evident after topical application of terbinafine, while 
the permeation into the systemic circulation is minimal 
as evidenced from pharmacokinetic studies in human 
volunteers and patients with tinea pedis  [36, 41, 45, 46] . 
Twenty healthy volunteers were randomized to receive 
terbinafine 1% cream applied to the upper back as a single 
dose, or once daily for 3, 5 or 7 consecutive days  [41] . Us-
ing the back as a model system for pharmacokinetic anal-
ysis of the skin is state of the art, and the data are trans-
ferable to those relevant to the skin of the foot as the skin 
is structured similarly  [47, 48] . For HPLC analysis, up to 
5 sequential skin surface biopsies were taken from the 
treatment areas, both during the application period and 
thereafter. Increasing the number of applications from 1 
to 7 did not significantly augment the peak concentration 
in the stratum corneum (about 1   g/cm 2 from day 1 to 
7). However, terbinafine was detectable for 7 days after 
cessation. After a 7-day application of terbinafine 1% 
cream, the biphasic elimination pattern of terbinafine 
from the stratum corneum (with a rapid decline over the 
first 12 h) showed a 3 times longer elimination half-life as 
compared to a single application. Moreover, the drug lev-
els significantly exceed the minimum fungicidal concen-
trations of most of the dermatophyte strains during the 
treatment course and at least 100-fold for 7 days following 
the last application  [41] .
 Long-lasting terbinafine concentrations in the skin 
with just a single application inspired the development of 
a formulation for single-dose therapy in patients with tin-
ea pedis. This became a reality using an FFS containing 
terbinafine 1%, ethanol and a bioadhesive acrylate/acryl-
amide copolymer matrix. Ethanol evaporates rapidly af-
ter the application of this FFS on the skin. The high con-
centration gradient results in pronounced terbinafine 
skin penetration, which is further facilitated by the alco-
hol  [49–51] . Moreover, the adhesion of the polymer ma-
trix inhibits the removal of terbinafine from the skin sur-
face and thus induces an ongoing absorption process for 
an additional few days – in the absence of early skin wash-
ing within the first 24 h after application  [36] .
 Terbinafine binds to corneocytes and remains there 
for a long period as demonstrated by a recent study in 36 
healthy subjects who applied terbinafine 1% FFS and 
cream on their back  [36] . Eleven consecutive tape strips 
were taken from defined treatment areas at baseline and 
1–312 h after application for drug determination by liq-
uid chromatography/mass spectroscopy. The drug 
amounts recovered by the tape strips were reported. Peak 
amounts in the stratum corneum following a single dose 
of both cream and FFS were obtained already at about 
1.5–2 h, yet the amounts obtained with the FFS (5.0   g/
cm 2 ) surpassed the peak value reached with the cream 
(2.0   g/cm 2 ) by  1 2-fold. The average AUC 0–168 h (area un-
der the concentration time curve) reflecting total drug 
within the horny layer over 7 days increased by 3-fold 
( table 1 ). When considering the entire dosing regimen, 
the average AUC 0–312 h with a single dose of terbinafine 
1% FFS was 84% of the exposure obtained with 7 days of 
cream treatment ( table 1 ). In other words, terbinafine 
stratum corneum exposure (AUC 0–312 h ) after single-dose 
treatment with FFS was nearly equivalent to 6 applica-
tions with terbinafine cream  [36] . With the FFS, 30% of 
the total drug delivered into the stratum corneum oc-
curred during the first 2 h, 31% from 2–12 h and 39% 
thereafter. Furthermore, 75% of the penetrated drug was 
Table 1. Mean stratum corneum pharmacokinetics of terbinafine 
following a single application of 1% terbinafine FFS and the cream 
(50 g/cm2 [36])
1% terbinafine
FFS
(single application)
1% terbinafine
cream
(single application)
Cmax, ng/cm2 4,952** 1,951a
t1/2, h 162* 68*
AUC (0–168 h), ng ! h/cm2 104,178** 35,770a, **
Cmax = Mean peak concentration. * p = 0.0004 (Wilcoxon 
signed rank test); ** p < 0.0001 (Student’s t test).
a Extrapolated data.
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within the outermost horny layer (strips 1–6) and 25% in 
the deeper layers (strips 7–11). The respective elimination 
half-life was 162 h for FFS and 68 h for the cream ( table 1 ). 
The elimination half-life for the cream is consistent with 
earlier results  [39, 41] . The terbinafine skin levels of 24 
ng/cm 2 at 13 days after a single application of the FFS 
were close to those seen 7 days after the final cream ap-
plication and exceeded the in vitro fungicidal concentra-
tions for dermatophytes ( [9–11, 36] ,  fig. 2 ).
 Overall, the pharmacokinetic study demonstrates the 
superior skin pharmacokinetic profile of terbinafine us-
ing the FFS. Interestingly, another film-forming formula-
tion based on a hydroxypropyl chitosan lacquer which 
allowed close contact and strong adhesion to the keratin 
matrix also increased ciclopirox penetration into thin 
membranes obtained from bovine hooves  [52] . This un-
derscores the potential of bioadhesive films for drug de-
livery in dermatotherapy.
 Systemic exposure of terbinafine following topical ap-
plication of 1% cream or 1% FFS was found to be very low 
both in healthy volunteers and in patients with dermato-
mycoses, i.e. tinea pedis or pityriasis versicolor. When ap-
plied for 8 h on skin with or without a reduced barrier 
function and with or without occlusion, terbinafine 1% 
cream resulted in a plasma concentration of 11.4 ng/ml. 
This approximates about 1% of the exposure following 
oral administration of a 250-mg tablet. A reduced barrier 
function did not result in higher values  [46] . There was 
no evidence of increased systemic exposure with long-
term application of terbinafine, since the maximum plas-
ma concentration observed in patients with pityriasis 
versicolor treated twice daily for 28 days showed similar 
results (24.8 ng/ml)  [46] . In 20 healthy volunteers, an ap-
plication of 3 times the proposed therapeutic dose of ter-
binafine 1% FFS (0.05 mg terbinafine/cm 2 ) resulted in 
blood exposure to terbinafine of  ! 0.5% of the exposure 
following oral administration of a 250-mg tablet  [36] . In 
14 patients with tinea pedis, a plasma level of terbinafine 
 1 1 ng/ml was measured in only 1 sample  [36] .
 The very low systemic absorption of terbinafine ob-
served following topical application in healthy volunteers 
and patients with cutaneous fungal infections confirms 
the systemic safety and suggests that the stratum corneum 
acts as both a barrier and a reservoir for the lipophilic ter-
binafine and that systemic absorption is not affected by 
the integrity or inflammation of the stratum corneum.
 Skin Pharmacokinetics of Other Antifungals 
 Other antifungal agents also accumulate in high con-
centrations in horny layers of the skin. Following topical 
occlusive application of 1% bifonazole or 1% clotrimazole 
cream (5 mg active agent, respectively) on the back of 
healthy volunteers, the half-lives of bifonazole retained in 
the horny layer ranged from 19 to 32 h and were nearly 
similar to those of clotrimazole. The quantity of bifon-
azole in the skin, however, was about twice as high as that 
of clotrimazole  [48] . When applied under occlusive con-
ditions as 1% solution or 1% cream (15 mg bifonazole) on 
the skin of volunteers with a contact time of 12 h, the bi-
fonazole concentrations in the stratum corneum exceed-
ed the minimum inhibitory concentration for most of the 
dermatophytes  [53] .
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 The results of studies in the guinea pig are in accor-
dance – fluconazole, itraconazole and griseofulvin build 
up high intracutaneous concentrations after oral or topi-
cal once-daily application and remain there for a certain 
period, e.g. up to 4 days for miconazole  [54, 55] . However, 
the concentrations of itraconazole and ketoconazole in the 
stratum corneum are low compared to those of terbin-
afine and fluconazole (at least after oral application)  [56] .
 As with terbinafine, the systemic absorption of topi-
cally applied azoles is low. In healthy volunteers, a single 
topical application of bifonazole as a 1% cream or a 1% 
solution with or without occlusion yielded bifonazole 
plasma levels  ! 1 ng/ml, representing approximately  ! 1% 
of the applied amount; repeated applications did not lead 
to levels exceeding 5 ng/ml  [53] .  Similar results were ob-
tained with topically applied clotrimazole and micon-
azole,  ! 2% of the applied amount  of these antifungal 
agents became systemically available  [57, 58] . Systemic ab-
sorption of bifonazole was affected by inflammation of 
the skin, since the absorbed amount increased by up to 4-
fold when applied on damaged skin [for review see  53 ].
 Binding of antifungal agents to keratin  [54, 59] de-
creases their in vitro antifungal activity  [54, 60] , but this 
binding is generally weak and reversible and hence can 
prolong retention in the skin  [44] . In summary antifun-
gal agents other than terbinafine also accumulate in high 
concentrations in horny layers of the skin, however, they 
require a longer duration of treatment to be efficacious 
probably because of their fungistatic mode of action.
 Effectiveness due to Fungicidal Activity and 
Reservoir Effect 
 The accumulation in the stratum corneum is described 
for many lipophilic drugs including terbinafine, azole an-
tifungals and glucocorticoids. The concentration of the 
active ingredient in the horny layer and the very slow 
elimination of the drug from this site play an important 
role in providing a long-term effect of terbinafine with 
continued increase in cure rates even after cessation of 
application. In fact, elimination from the stratum cor-
neum is most likely more closely linked to the physiolog-
ical skin turnover than to absorption into the blood 
stream.
 As a reservoir effect is not only seen with terbinafine 
but has also been described for azole antifungal drugs 
 [52–55, 61–64] , the improved efficacy of terbinafine in 
managing cutaneous fungal infections (especially when 
caused by dermatophytes) may be due to the combination 
of accumulation in the horny layer and its potent fungi-
cidal mode of action. As the minimum fungicidal con-
centrations of terbinafine against dermatophytes are very 
low compared to the azole antifungals, terbinafine prob-
ably exerts its antifungal activity as long as the drug is 
detectable in the skin. At the same time the terbinafine 
plasma concentrations are clearly below the skin levels in 
healthy volunteers and in patients with hyperkeratotic 
tinea pedis  [36, 41, 45] . This leads to a notably long-last-
ing fungicidal action beyond the treatment period in the 
skin. In summary, the combination of reservoir effect 
and fungicidal activity of terbinafine even at low concen-
trations allows a 1-week treatment with cream, gel and 
spray solution, or just a single-application treatment with 
the new FFS formulation.
 Conclusion 
 The pronounced fungicidal effect of terbinafine plus 
the accumulation within and slow elimination from the 
stratum corneum, in other words the reservoir effect of 
the drug, in principle make short-term therapy with ter-
binafine for tinea pedis feasible – either as once-daily 7-
day treatment with cream or a single-dose treatment us-
ing the FFS. The FFS ensures skin contact for a sufficient-
ly long time and provides a high concentration gradient 
favoring terbinafine penetration into the horny layer, 
which is the site of dermatophyte infection. Thus, a high-
ly active pharmaceutical agent coupled with a distinct 
reservoir effect facilitated by the characteristics of the ve-
hicle are very important for an efficacious and conve-
nient therapy. The new terbinafine FFS looks particular-
ly apt to allow a single-dose therapy of tinea pedis. 
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